Ranbaxy looks to leave past behind after US settlement
This article was originally published in Scrip
Executive Summary
Ranbaxy's $500 million settlement towards an investigation by the US Department of Justice (DOJ) concerning data integrity and manufacturing processes at two of the firm's Indian sites is expected to help bring down the curtains on a long-running issue that has troubled Daiichi Sankyo since it acquired Ranbaxy in 2008, and which has been high on the list of investor concerns.